A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder

References (50)

1. World Health Organization. Depression. https://www.who.int/news-room/fact-sheets/detail/depression. Published January 30, 2020. Accessed July 4, 2021.
2. Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci. 2008;10(4):409–418. PubMed CrossRef
3. Lee EE, Della Selva MP, Liu A, et al. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry. 2015;37(2):178–184. PubMed CrossRef
4. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231(18):3663–3676. PubMed CrossRef
5. Marcantoni WS, Akoumba BS, Wassef M, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009–January 2019. J Affect Disord. 2020;277:831–841. PubMed CrossRef
6. Canady VA. FDA approves esketamine treatment for MDD, suicidal ideation. Ment Health Wkly. 2020;30(31):6–7. CrossRef
7. Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000 Res. 2018;7:659. CrossRef
8. Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121–1129. PubMed CrossRef
9. Drevets WC, Furey ML. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67(5):432–438. PubMed CrossRef
10. Furey ML, Khanna A, Hoffman EM, et al. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology. 2010;35(12):2479–2488. PubMed CrossRef
11. Ellis JS, Zarate CA Jr, Luckenbaugh DA, et al. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications. J Affect Disord. 2014;162:39–42. PubMed CrossRef
12. Park L, Furey M, Nugent AC, et al. Neurophysiological changes associated with antidepressant response to ketamine not observed in a negative trial of scopolamine in major depressive disorder. Int J Neuropsychopharmacol. 2019;22(1):10–18. PubMed CrossRef
13. Mirakhur RK, Dundee JW. Glycopyrrolate: pharmacology and clinical use. Anaesthesia. 1983;38(12):1195–1204. PubMed CrossRef
14. Chen JCC, Sumner RL, Krishnamurthy Naga V, et al. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder. Trials. 2020;21(1):157. PubMed CrossRef
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Publishing; 2013.
16. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
17. Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192(1):52–58. PubMed CrossRef
18. Rutherford BR, Marcus SM, Wang P, et al. A randomized, prospective pilot study of patient expectancy and antidepressant outcome. Psychol Med. 2013;43(5):975–982. PubMed CrossRef
19. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. PubMed CrossRef
20. Martin CS, Earleywine M, Musty RE, et al. Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res. 1993;17(1):140–146. PubMed CrossRef
21. Judd LL, Hubbard RB, Huey LY, et al. Lithium carbonate and ethanol induced “highs” in normal subjects. Arch Gen Psychiatry. 1977;34(4):463–467. PubMed CrossRef
22. Bremner JD, Krystal JH, Putnam FW, et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress. 1998;11(1):125–136. PubMed CrossRef
23. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31(suppl 2):80–84. PubMed CrossRef
24. Rief W, Barsky AJ, Glombiewski JA, et al. Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf. 2011;20(4):405–415. PubMed CrossRef
25. Bowdle TA, Radant AD, Cowley DS, et al. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998;88(1):82–88. PubMed CrossRef
26. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–191. PubMed CrossRef
27. Chen YHJ, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising. Stat Med. 2004;23(7):1023–1038. PubMed CrossRef
28. Chen YH, Li C, Lan KK. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials. Clin Trials. 2015;12(6):584–595. PubMed CrossRef
29. R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. https://www.r-project.org/. 2020. Accessed June 22, 2021.
30. Zuurman L, Roy C, Schoemaker RC, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol. 2008;22(7):707–716. PubMed CrossRef
31. Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One. 2010;5(8):e12412. PubMed CrossRef
32. Harden RN, Saracoglu M, Connolly S, et al. “Managing” the placebo effect: the single-blind placebo lead-in response in two pain models. Pain Med. 2016;17(12):2305–2310. PubMed CrossRef
33. Faries DE, Heiligenstein JH, Tollefson GD, et al. The double-blind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol. 2001;21(6):561–568. PubMed CrossRef
34. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res. 1992;41(3):203–214. PubMed CrossRef
35. Fairchild CJ, Rush AJ, Vasavada N, et al. Which depressions respond to placebo? Psychiatry Res. 1986;18(3):217–226. PubMed CrossRef
36. Sullivan MD, Katon WJ, Russo JE, et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J Am Board Fam Pract. 2003;16(1):22–31. PubMed CrossRef
37. Wilkinson ST, Farmer C, Ballard ED, et al. Impact of midazolam vs saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology. 2019;44(7):1233–1238. PubMed CrossRef
38. Yaroslavsky I, Rottenberg J, Bylsma LM, et al. Parasympathetic nervous system activity predicts mood repair use and its effectiveness among adolescents with and without histories of major depression. J Abnorm Psychol. 2016;125(3):323–336. PubMed CrossRef
39. De Ferrari GM, Mantica M, Vanoli E, et al. Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. J Am Coll Cardiol. 1993;22(5):1327–1334. PubMed CrossRef
40. La Rovere MT, Mortara A, Pantaleo P, et al. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation. 1994;90(2):838–843. PubMed CrossRef
41. Vybiral T, Bryg RJ, Maddens ME, et al. Effects of transdermal scopolamine on heart rate variability in normal subjects. Am J Cardiol. 1990;65(9):604–608. PubMed CrossRef
42. Haddad EB, Patel H, Keeling JE, et al. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol. 1999;127(2):413–420. PubMed CrossRef
43. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 1992;260(2):576–580. PubMed
44. Drevets WC, Zarate CA Jr, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 2013;73(12):1156–1163. PubMed CrossRef
45. Duman RS. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety. 2014;31(4):291–296. PubMed CrossRef
46. Ghosal S, Bang E, Yue W, et al. Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine. Biol Psychiatry. 2018;83(1):29–37. PubMed CrossRef
47. Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry. 2021;178(4):352–362. PubMed CrossRef
48. Shiroma PR, Thuras P, Wels J, et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10(1):206. PubMed CrossRef
49. McMillan R, Sumner R, Forsyth A, et al. Simultaneous EEG/fMRI recorded during ketamine infusion in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109838. PubMed CrossRef
50. Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev Clin Pharmacol. 2021;14(9):1133–1152. PubMed CrossRef